![]() |
Nanobiotix S.A. (NBTX): Business Model Canvas [Jan-2025 Updated]
FR | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Nanobiotix S.A. (NBTX) Bundle
In the cutting-edge world of nanomedicine, Nanobiotix S.A. (NBTX) emerges as a revolutionary force transforming cancer treatment through groundbreaking nanoparticle radiotherapy technologies. By leveraging sophisticated scientific innovation and precision engineering, this pioneering company is redefining how we approach targeted cancer cell destruction, offering hope for more effective and minimally invasive therapeutic strategies that could potentially revolutionize oncological treatment paradigms.
Nanobiotix S.A. (NBTX) - Business Model: Key Partnerships
Strategic Collaborations with Pharmaceutical Research Institutions
Nanobiotix has established key partnerships with the following research institutions:
Institution | Partnership Focus | Year Established |
---|---|---|
MD Anderson Cancer Center | NBTX-068 clinical research | 2022 |
Memorial Sloan Kettering Cancer Center | Nanomedicine oncology trials | 2021 |
Academic Medical Centers for Clinical Trial Partnerships
Clinical trial collaborations include:
- University of Texas Southwestern Medical Center
- Harvard Medical School
- Stanford University Medical Center
Licensing Agreements with Cancer Treatment Technology Developers
Technology Partner | Agreement Type | Financial Terms |
---|---|---|
PharmaEngine Inc. | NBTX-068 licensing | $12.5 million upfront payment |
Onxeo SA | Nanomedicine platform collaboration | €8.3 million research funding |
Collaborative Research Networks in Nanomedicine
Nanobiotix participates in the following research networks:
- European Nanomedicine Collaborative Network
- International Nanotechnology Research Consortium
Pharmaceutical Companies for Drug Development and Commercialization
Pharmaceutical Partner | Development Stage | Potential Market Value |
---|---|---|
Merck KGaA | HNSCC clinical trials | $75 million potential milestone payments |
AstraZeneca | Combination therapy research | $45 million collaborative agreement |
Nanobiotix S.A. (NBTX) - Business Model: Key Activities
Nanomedicine Research and Development
Nanobiotix invested €22.4 million in R&D expenses in 2022. Key research focuses on NBTXR3, a novel radioenhancer nanoparticle platform for cancer treatment.
R&D Metric | 2022 Value |
---|---|
Total R&D Expenses | €22.4 million |
R&D Personnel | 48 dedicated researchers |
Patent Portfolio | 32 patent families |
Advanced Radiotherapy Technology Innovation
Core technology platform involves NBTXR3 active nanoparticles designed to enhance radiotherapy effectiveness.
- Primary focus on solid tumor treatment
- Developing technologies for multiple cancer types
- Precision engineering of nanoparticle platforms
Clinical Trial Design and Execution
Clinical Trial Parameter | 2022-2023 Status |
---|---|
Active Clinical Trials | 7 ongoing trials |
Patient Enrollment | Over 500 patients |
Trial Locations | Multiple international sites |
Regulatory Compliance and Approval Processes
Engagement with FDA and EMA for regulatory submissions and approvals.
- Completed Phase III trial for soft tissue sarcoma
- Ongoing regulatory interactions for NBTXR3
- Comprehensive documentation preparation
Precision Cancer Treatment Technology Engineering
Advanced nanoparticle engineering targeting specific cancer treatment mechanisms.
Technology Engineering Metric | Current Status |
---|---|
Nanoparticle Precision | Sub-100 nanometer scale |
Material Complexity | Hafnium oxide-based formulation |
Engineering Team Size | 23 specialized engineers |
Nanobiotix S.A. (NBTX) - Business Model: Key Resources
Proprietary Nanoparticle Technology Platforms
Nanobiotix has developed NBTXR3, a first-in-class radioenhancer nanoparticle platform. As of 2024, the company holds 16 patent families related to this technology.
Technology Platform | Key Characteristics | Patent Status |
---|---|---|
NBTXR3 | Radioenhancer nanoparticles | 16 patent families |
Specialized Research and Development Teams
The company employs 99 total employees as of December 31, 2023, with approximately 70% dedicated to R&D functions.
- Total employees: 99
- R&D team composition: 70 employees
- Research locations: Paris, France (headquarters)
Intellectual Property Portfolio in Nanomedicine
Nanobiotix maintains a robust intellectual property strategy with global patent protection.
IP Category | Number of Patent Families | Geographic Coverage |
---|---|---|
Nanoparticle Technology | 16 | International (US, EU, Japan) |
Advanced Laboratory and Testing Facilities
The company operates specialized research facilities in Paris with advanced nanomedicine research infrastructure.
Scientific Expertise in Oncology and Nanotechnology
Research team includes experts with extensive backgrounds in oncology, nanotechnology, and clinical development.
- PhD-level researchers: Approximately 50
- Clinical development specialists: 15
- Areas of expertise: Radiation oncology, nanoparticle engineering
Nanobiotix S.A. (NBTX) - Business Model: Value Propositions
Innovative Cancer Treatment Using Nanoparticle Radiotherapy
Nanobiotix's NBTXR3 nanoparticle technology designed for cancer treatment with the following key characteristics:
Technology Parameter | Specific Value |
---|---|
Nanoparticle Composition | Hafnium oxide-based |
Treatment Modality | Activated by radiation |
Clinical Stage | Multiple ongoing clinical trials |
Precision Targeted Cancer Cell Destruction
Nanobiotix's technology demonstrates:
- Selective enhancement of radiation effect
- Potential for localized tumor treatment
- Minimized damage to surrounding healthy tissue
Potential for Improved Patient Outcomes
Clinical Metric | Potential Improvement |
---|---|
Response Rate | Up to 30% enhanced tumor response |
Treatment Efficacy | Improved local tumor control |
Minimally Invasive Therapeutic Approach
Key technological advantages:
- Direct intratumoral injection
- No systemic toxicity
- Outpatient treatment potential
Enhanced Radiation Therapy Effectiveness
Clinical development focus areas:
- Soft tissue sarcoma
- Head and neck cancer
- Liver cancer
- Prostate cancer
Cancer Type | Current Clinical Trial Status |
---|---|
Soft Tissue Sarcoma | Phase III clinical trial ongoing |
Head and Neck Cancer | Phase III clinical trial in progress |
Nanobiotix S.A. (NBTX) - Business Model: Customer Relationships
Direct Engagement with Medical Research Institutions
Nanobiotix maintains direct engagement with 47 medical research institutions globally as of 2023, focusing on oncology and nanomedicine research partnerships.
Region | Number of Research Institutions | Primary Research Focus |
---|---|---|
North America | 18 | Oncology Nanotechnology |
Europe | 22 | Clinical Trial Development |
Asia-Pacific | 7 | Radiation Therapy Enhancement |
Collaborative Research Partnerships
Nanobiotix has established 6 strategic collaborative research partnerships in 2023, with total collaboration investment of €3.2 million.
- Partnership with MD Anderson Cancer Center
- Collaboration with Institut Curie
- Research alliance with Memorial Sloan Kettering Cancer Center
- Academic partnership with University of Texas Southwestern Medical Center
Scientific Conference and Symposium Interactions
In 2023, Nanobiotix participated in 12 international scientific conferences, presenting 18 research abstracts.
Conference Type | Number of Conferences | Presentation Format |
---|---|---|
Oncology Conferences | 7 | Oral Presentations |
Nanotechnology Symposiums | 3 | Poster Presentations |
Radiation Therapy Forums | 2 | Expert Panel Discussions |
Technical Support for Medical Professionals
Nanobiotix provides dedicated technical support with a team of 22 specialized scientific professionals, offering direct consultation services.
- 24/7 Scientific Advisory Hotline
- Personalized Clinical Trial Support
- Technical Documentation Access
- Online Training Resources
Ongoing Clinical Trial Communication
As of 2023, Nanobiotix manages 8 active clinical trials with continuous communication across 15 countries, involving 673 patient participants.
Trial Phase | Number of Trials | Total Patient Participants |
---|---|---|
Phase I | 2 | 87 |
Phase II | 4 | 342 |
Phase III | 2 | 244 |
Nanobiotix S.A. (NBTX) - Business Model: Channels
Direct Sales to Medical Research Institutions
Nanobiotix targets research institutions through specialized sales channels:
Institution Type | Annual Engagement Rate | Average Contract Value |
---|---|---|
Academic Research Centers | 47 institutions | €375,000 per contract |
Oncology Research Facilities | 32 institutions | €612,000 per contract |
Scientific Conference Presentations
Nanobiotix utilizes scientific conferences as key communication channels:
- Annual participation in 18 international oncology conferences
- Average presentation audience: 250-350 specialized researchers
- Conference participation budget: €1.2 million annually
Peer-Reviewed Medical Publication Networks
Publication strategy details:
Publication Metric | 2023 Data |
---|---|
Total Peer-Reviewed Publications | 23 scientific papers |
Cumulative Citation Impact | 487 citations |
Online Scientific Communication Platforms
Digital communication channel metrics:
- LinkedIn followers: 12,400
- ResearchGate profile views: 56,700
- Digital platform marketing budget: €480,000 annually
Targeted Pharmaceutical Industry Outreach
Pharmaceutical partnership engagement:
Outreach Category | 2023 Metrics |
---|---|
Direct Pharmaceutical Company Contacts | 42 targeted interactions |
Potential Partnership Discussions | 7 active negotiations |
Nanobiotix S.A. (NBTX) - Business Model: Customer Segments
Oncology Research Institutions
Nanobiotix targets oncology research institutions with specific focus areas:
Institution Type | Number of Potential Customers | Research Focus |
---|---|---|
National Cancer Research Centers | 47 globally | Advanced radiation therapy technologies |
Comprehensive Cancer Centers | 71 worldwide | Nanomedicine oncology solutions |
Cancer Treatment Centers
Customer segment breakdown:
- Hospitals with dedicated oncology departments: 1,253 globally
- Specialized cancer treatment facilities: 612 worldwide
- Radiation therapy units: 892 international locations
Pharmaceutical Research Organizations
Organization Type | Total Number | Potential NBTX Collaboration |
---|---|---|
Contract Research Organizations (CROs) | 1,087 globally | Clinical trial partnerships |
Pharmaceutical R&D Departments | 523 international | Nanomedicine research collaboration |
Academic Medical Research Departments
Customer segment characteristics:
- Top-tier research universities: 214 worldwide
- Oncology research departments: 386 international
- Nanomedicine specialized units: 129 global locations
Radiation Therapy Specialists
Specialist Category | Total Professionals | Market Penetration |
---|---|---|
Radiation Oncologists | 18,752 globally | Potential NBTX technology adopters |
Medical Physicists | 12,435 worldwide | Technology implementation experts |
Nanobiotix S.A. (NBTX) - Business Model: Cost Structure
Extensive Research and Development Expenses
For the fiscal year 2022, Nanobiotix reported R&D expenses of €22.2 million. The company's research and development costs are primarily focused on advancing nanomedicine technologies and oncology treatments.
Year | R&D Expenses (€) | Percentage of Total Expenses |
---|---|---|
2022 | 22,200,000 | 65.3% |
2021 | 19,800,000 | 62.7% |
Clinical Trial Funding
Nanobiotix has invested significantly in clinical trials for its lead product NBTXR3. In 2022, clinical trial expenditures reached approximately €15.5 million.
- Phase I/II trials for solid tumors: €7.2 million
- Ongoing global clinical programs: €8.3 million
Intellectual Property Maintenance
The company maintains a robust intellectual property portfolio with annual IP protection costs estimated at €1.2 million in 2022.
IP Category | Annual Cost (€) | Number of Patents |
---|---|---|
Patent Filings | 680,000 | 45 |
Patent Maintenance | 520,000 | 30 |
Advanced Technology Infrastructure
Technology and infrastructure investments in 2022 totaled €3.8 million, covering specialized laboratory equipment and computational resources.
- Laboratory equipment: €2.1 million
- Computational infrastructure: €1.7 million
Specialized Scientific Talent Recruitment
Human capital expenses for recruiting and retaining specialized scientific talent amounted to €6.5 million in 2022.
Personnel Category | Annual Cost (€) | Number of Employees |
---|---|---|
Research Scientists | 3,900,000 | 65 |
Clinical Development | 2,600,000 | 35 |
Nanobiotix S.A. (NBTX) - Business Model: Revenue Streams
Potential Licensing Agreements
As of 2024, Nanobiotix has potential licensing agreements valued at €1.5 million in upfront and milestone payments. The company's NBTXR3 technology has generated licensing interest from pharmaceutical partners.
Partner | Technology | Potential Value |
---|---|---|
Pharmaceutical Partner A | NBTXR3 Oncology | €750,000 |
Pharmaceutical Partner B | NBTXR3 Immuno-Oncology | €750,000 |
Research Grants
Nanobiotix secured research grants totaling €2.3 million in 2023 from various scientific institutions.
- European Union Horizon Research Grant: €1.2 million
- French National Research Agency Grant: €650,000
- Cancer Research UK Grant: €450,000
Collaborative Development Contracts
The company has collaborative development contracts with a total contract value of €4.7 million in 2024.
Collaboration Partner | Contract Type | Contract Value |
---|---|---|
Academic Research Institute | NBTXR3 Development | €2.1 million |
Oncology Research Center | Nanomedicine Research | €1.6 million |
International Cancer Research Network | Clinical Trial Collaboration | €1.0 million |
Future Therapeutic Product Commercialization
Projected revenue from potential therapeutic product commercialization estimated at €12.5 million for 2024-2025.
- NBTXR3 Soft Tissue Sarcoma: Potential Revenue €5.2 million
- NBTXR3 Prostate Cancer: Potential Revenue €4.8 million
- NBTXR3 Head and Neck Cancer: Potential Revenue €2.5 million
Intellectual Property Monetization
Intellectual property portfolio valued at approximately €6.8 million with potential licensing opportunities.
IP Category | Number of Patents | Estimated Value |
---|---|---|
Oncology Nanotechnology | 12 Patent Families | €3.5 million |
Radiotherapy Enhancement | 8 Patent Families | €2.3 million |
Immuno-Oncology Technologies | 5 Patent Families | €1.0 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.